|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-9-7
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Akt is a central regulator of cell growth. Its activity can be negatively regulated by the phosphatase PHLPP that specifically dephosphorylates the hydrophobic motif of Akt (Ser473 in Akt1). However, how PHLPP is targeted to Akt is not clear. Here we show that FKBP51 (FK506-binding protein 51) acts as a scaffolding protein for Akt and PHLPP and promotes dephosphorylation of Akt. Furthermore, FKBP51 is downregulated in pancreatic cancer tissue samples and several cancer cell lines. Decreased FKBP51 expression in cancer cells results in hyperphosphorylation of Akt and decreased cell death following genotoxic stress. Overall, our findings identify FKBP51 as a negative regulator of the Akt pathway, with potentially important implications for cancer etiology and response to chemotherapy.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PHLPP1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphoprotein Phosphatases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/tacrolimus binding protein 5
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1878-3686
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
8
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
259-66
|
|
pubmed:dateRevised |
2010-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:19732725-Antimetabolites, Antineoplastic,
pubmed-meshheading:19732725-Antineoplastic Agents,
pubmed-meshheading:19732725-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:19732725-Cell Line,
pubmed-meshheading:19732725-Cell Line, Tumor,
pubmed-meshheading:19732725-Cytarabine,
pubmed-meshheading:19732725-Drug Therapy,
pubmed-meshheading:19732725-Humans,
pubmed-meshheading:19732725-Kidney,
pubmed-meshheading:19732725-Neoplasms,
pubmed-meshheading:19732725-Nuclear Proteins,
pubmed-meshheading:19732725-Paclitaxel,
pubmed-meshheading:19732725-Pancreatic Neoplasms,
pubmed-meshheading:19732725-Phosphoprotein Phosphatases,
pubmed-meshheading:19732725-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:19732725-Tacrolimus Binding Proteins,
pubmed-meshheading:19732725-Taxoids
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.
|
|
pubmed:affiliation |
Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
